Positive 16 Sep, 21:30 Impact +5

Eli Lilly and Company (NYSE:LLY) today announced positive topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes

Negative 16 Sep, 21:30 Impact +5

Eli Lilly Announces Price Reduction for Weight Loss Drug Zepbound

Positive 16 Sep, 21:30 Impact +5

Eli Lilly's New Obesity Treatment Shows Significant Weight Loss and Knee Pain Reduction

Regulatory 16 Sep, 21:30 Impact +5

FDA Pressures Eli Lilly for Faster Decision on Weight Loss Drug

Positive 16 Sep, 21:30 Impact +5

Eli Lilly Reduces Obesity Drug Prices in China Following Novo Nordisk's Lead

AI 16 Sep, 21:30 Impact +5

NVIDIA Invests $1 Billion Over Five Years in AI Drug Development Lab with Eli Lilly

Regulatory 16 Sep, 21:30 Impact +5

Eli Lilly's Sofetabart Mipitikan Receives FDA Breakthrough Therapy Designation

Positive 16 Sep, 21:30 Impact +5

Eli Lilly Signs $1.12 Billion Agreement with Seamless Therapeutics for Hearing Loss Treatments

Earnings 16 Sep, 21:30 Impact +5

Eli Lilly Reports Strong Q3 Earnings and Raises 2026 Revenue Forecast

Neutral 16 Sep, 21:30 Impact +5

Eli Lilly Acquires Orna Therapeutics for $2.4 Billion

Positive 16 Sep, 21:30 Impact +5

Eli Lilly's Olumiant Receives Positive Opinion for Treating Severe Alopecia in Adolescents

Positive 16 Sep, 21:30 Impact +5

Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion

Positive 10 Aug, 22:03 Impact +7

Eli Lilly’s Foundayo Receives First European Approval in the UK

Positive 5 Aug, 16:32 Impact +5

Eli Lilly (LLY) Opens Over 5% Higher Amid S&P 500 Alerts

Positive 29 Jul, 10:53 Impact +5

Eli Lilly Achieves 43.5% Stock Increase Since April, Approaches Top 10 Global Market Capitalization